Delving into the Latest Updates on Ketamine Hydrochloride with Synapse

Overview

Basic Info

SummaryKetamine is a small molecule drug that acts as a modulator at the N-methyl-D-aspartate (NMDA) receptor. It is marketed under the trade name KETALAR and is primarily used as an anesthetic drug. Ketamine was first approved for medical use in the United States in 1970 by Endo International. This drug is available as a slightly acidic, sterile solution for intravenous or intramuscular injection. Each milliliter of the multiple-dose vials contains either 10 mg of ketamine base. Ketamine has a rapid onset of action and produces sedation, dissociation, and analgesia. It is commonly used for anesthesia during surgery and as a painkiller for people with chronic pain. Ketamine may have some potential as an antidepressant, but more research is needed to determine its efficacy and safety for this indication. The use of ketamine as an anesthetic or painkiller may cause some side effects, including hallucinations, nausea, and vomiting.

Drug Type

Small molecule drug

Synonyms

(+-)-Ketamine, (±)-ketamine, 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone

+ [41]

Target

NMDA receptor

Action

modulators

Mechanism

NMDA receptor modulators(Glutamate [NMDA] receptor modulators)

Therapeutic Areas

Nervous System DiseasesOther DiseasesCongenital Disorders+ [6]

Active Indication

PainAnesthesiaSuicidal Ideation+ [19]

Inactive Indication

Amyotrophic Lateral SclerosisAutism Spectrum DisorderBunion+ [4]

Originator Organization

Endo International Plc

Active Organization

Neurocentrx Pharma Ltd.HolsboerMaschmeyer NeuroChemie (Germany)

iX Biopharma Ltd.

+ [18]

Inactive Organization

Novartis Pharma AG

Roivant Sciences, Inc.

Novartis AG

+ [2]

License Organization

Seelos Therapeutics, Inc.

Nephron Pharmaceuticals LLC

Kymanox Corp.

+ [13]

Drug Highest PhaseApproved

First Approval Date

United States (19 Feb 1970),

Anesthesia

RegulationFast Track (United States), Orphan Drug (United States), Innovative Licensing and Access Pathway (United Kingdom), Commissioner's National Priority Voucher (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC13H17Cl2NO

InChIKeyVCMGMSHEPQENPE-UHFFFAOYSA-N

CAS Registry1867-66-9

This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for Post Traumatic Stress Disorder (PTSD) utilizing an adaptive platform trial (APT) design.
Intervention D - SLS-002 will assess the safety and efficacy of SLS-002 in participants with PTSD.
Please see NCT05422612 for information on the S-21-02 Master Protocol.

Start Date01 May 2028

Sponsor / Collaborator

Cambridge Cognition Ltd.

[+5]

100 Clinical Results associated with Ketamine Hydrochloride

Login to view more data

100 Translational Medicine associated with Ketamine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Ketamine Hydrochloride

Login to view more data

28,071

Literatures (Medical) associated with Ketamine Hydrochloride

31 Dec 2026·Canadian Journal of Pain-Revue Canadienne de la Douleur

PAINscape—Exploring patient experiences with ketamine for chronic neuropathic pain: A qualitative study

Article

Author: Mattina, Gabriella ; Lu, Mindy ; Parakh, Nandana ; Goel, Akash ; Ladha, Karim S ; Tucci, Victoria ; Hanlon, John G ; Ritvo, Paul ; Pritlove, Cheryl ; Leda, Mariela ; Clarke, Hance ; Dang, Kevin ; Rizvi, Sakina J ; Pazmino-Canizares, Janneth ; Thomas, Zaaria ; Wijeysundera, Duminda N ; Lessor, Danielle ; Pereira, Sérgio M ; Nayar, Roshni

Background/Aims:

Chronic pain affects approximately 8 million Canadians annually and is defined by persistent pain lasting over 3 months. Ketamine is an anesthetic drug used to treat chronic neuropathic pain, a subset of chronic pain. To better understand ketamine's therapeutic benefits and feasibility as a treatment for chronic neuropathic pain, it is important to characterize patient experiences and perspectives with ketamine, as well as barriers and facilitators to accessing this treatment.

Methods:

Thirteen participants were recruited from the chronic pain ketamine infusion program at St. Michael's Hospital in Toronto, Canada. Each participant completed a survey that captured demographic information and chronic pain features, followed by a semistructured interview. Interview data were analyzed, and themes were generated using content analysis.

Results:

All participants described decreased pain intensity and increased functionality after receiving ketamine treatment. Barriers to ketamine treatment included fragmented health systems and long wait times, along with a struggle for pain validation by health care providers. Facilitators of ketamine treatment included support from individual health care providers and the provision of a supportive treatment environment.

Conclusions:

Although pain experiences differed among participants, all participants reported decreased pain with ketamine infusions. Addressing the stigma associated with ketamine infusions, further research around augmenting durability of ketamine, and providing a safe treatment environment can all improve ketamine's benefit for chronic neuropathic pain. Understanding the barriers and facilitators, as well as implementing participant suggestions, will not only help inform our ketamine program but can improve access to pain management and facilitate future research in this field.

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Ketamine enantiomers and the gut microbiota: mechanisms, clinical implications, and future directions

Review

Author: Zhou, Li-Wen ; Xie, Jin-Xi

01 Dec 2026·Current Pain and Headache Reports

Neuroscientific Basis of Ketamine as an Analgesic and Emerging Role in the Management of Depression

Review

Author: Kaye, Alan D ; Shekoohi, Sahar ; Meyer, Tricia A ; Coggins, Navy C ; Chokr, Hanson A ; Patel, Mihir

876

News (Medical) associated with Ketamine Hydrochloride

19 Jun 2026

·solvonis.com

Solvonis Announces Result of Annual General Meeting

LONDON – June 19, 2026 – Solvonis Therapeutics plc (LSE: SVNS) (“Solvonis” or the “Company”), a late clinical stage biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces that at the Annual General Meeting of the Company held earlier today, all resolutions put to shareholders were duly passed. Voting on all resolutions was conducted by way of a poll. Full details of the poll results are set out below. Dennis Purcell, Non-Executive Chairman of Solvonis, commented: “On behalf of the Board, I would like to thank shareholders for their continued support at today’s Annual General Meeting. “The past year has been an important period in the development of Solvonis, during which the Company completed its transition into a focused CNS therapeutics business and established a broader, more coherent portfolio across addiction and psychiatry. “We are pleased with the balanced progress being made across the portfolio, including our later-stage clinical programmes in Alcohol Use Disorder and our emerging discovery and preclinical opportunities in PTSD, stimulant use disorder and depression. “The Board remains focused on disciplined execution, capital-efficient development and creating long-term value for shareholders. We look forward to updating the market, as appropriate, on continued progress across the portfolio through the remainder of 2026.” The Company’s strategy is to build a differentiated CNS therapeutics portfolio across areas of high unmet need, with later-stage clinical assets complemented by internally generated discovery programmes. Solvonis’ current portfolio includes SVN-001, its lead programme in severe Alcohol Use Disorder; SVN-002, its U.S.-focused Alcohol Use Disorder programme; and discovery and preclinical programmes including SVN-114 in PTSD and SVN-015 in stimulant use disorder and depression. Voting Results: Resolution Votes for % Votes Cast Votes against % Votes Cast Total Votes Votes withheld Resolution 1 (Ordinary)To receive the report and accounts for the year ended 31 December 2025 1,155,565,533 96.16% 46,093,340 3.84% 1,201,658,873 1,589,104 Resolution 2 (Ordinary)To approve the remuneration policy 1,113,689,240 95.46% 52,967,133 4.54% 1,166,656,373 36,591,604 Resolution 3 (Ordinary)To approve the remuneration report 1,113,689,240 95.46% 52,967,133 4.54% 1,166,656,373 36,591,604 Resolution 4 (Ordinary)To re-appoint Kreston Reeves LLP as auditor 1,197,595,249 99.53% 5,652,728 0.47% 1,203,247,977 0 Resolution 5 (Ordinary)To re-appoint Paul Carter as a director 1,151,080,001 95.66% 52,167,976 4.34% 1,203,247,977 0 Resolution 6 (Ordinary)To re-appoint Anthony Tennyson as a director 1,151,313,351 99.49% 5,934,626 0.51% 1,157,247,977 46,000,000 Resolution 7 (Ordinary)To re-appoint Nicholas Nelson as a director 1,151,080,001 95.66% 52,167,976 4.34% 1,203,247,977 0 Resolution 8 (Ordinary)To authorise the directors to allot equity 1,146,194,662 95.26% 57,053,315 4.74% 1,203,247,977 0 Resolution 9 (Special)That a general meeting, other than an AGM, may be called on not less than 14 days’ notice 1,162,592,749 96.62% 40,655,228 3.38% 1,203,247,977 0 Resolution 10 (Special) To disapply pre-emption rights 1,026,314,705 94.85% 55,700,737 5.15% 1,082,015,442 121,232,535 Resolution Votes for % Votes Cast Votes against % Votes Cast Total Votes Votes withheld Resolution 1 (Ordinary) To receive the report and accounts for the year ended 31 December 2025 1,155,565,533 96.16% 46,093,340 3.84% 1,201,658,873 1,589,104 Resolution 2 (Ordinary) To approve the remuneration policy 1,113,689,240 95.46% 52,967,133 4.54% 1,166,656,373 36,591,604 Resolution 3 (Ordinary) To approve the remuneration report 1,113,689,240 95.46% 52,967,133 4.54% 1,166,656,373 36,591,604 Resolution 4 (Ordinary) To re-appoint Kreston Reeves LLP as auditor 1,197,595,249 99.53% 5,652,728 0.47% 1,203,247,977 0 Resolution 5 (Ordinary) To re-appoint Paul Carter as a director 1,151,080,001 95.66% 52,167,976 4.34% 1,203,247,977 0 Resolution 6 (Ordinary) To re-appoint Anthony Tennyson as a director 1,151,313,351 99.49% 5,934,626 0.51% 1,157,247,977 46,000,000 Resolution 7 (Ordinary) To re-appoint Nicholas Nelson as a director 1,151,080,001 95.66% 52,167,976 4.34% 1,203,247,977 0 Resolution 8 (Ordinary) To authorise the directors to allot equity 1,146,194,662 95.26% 57,053,315 4.74% 1,203,247,977 0 Resolution 9 (Special) That a general meeting, other than an AGM, may be called on not less than 14 days’ notice 1,162,592,749 96.62% 40,655,228 3.38% 1,203,247,977 0 Resolution 10 (Special) To disapply pre-emption rights 1,026,314,705 94.85% 55,700,737 5.15% 1,082,015,442 121,232,535 As at 19 June 2026, there were 6,806,403,493 ordinary shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and have not been included in the calculation of the proportion of votes for or against a resolution. The full text of each resolution is available in the Notice of Annual General Meeting, published on the Company's website. Enquiries: Solvonis Therapeutics plcAnthony Tennyson, CEO & Executive Directorinfo@solvonis.comSinger Capital Markets (Broker)Russell Cook+44 (0) 20 7496 3000 About Solvonis Therapeutics plc Solvonis Therapeutics plc (LSE: SVNS) is a late clinical-stage biopharmaceutical company developing small-molecule therapeutics for high-burden central nervous system (“CNS”) disorders. Headquartered in London and listed on the Main Market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline across addiction and psychiatry, combining later-stage clinical programmes with proprietary discovery-stage assets. The Company’s lead clinical programme, SVN-001, is currently in Phase 3 for severe Alcohol Use Disorder (“AUD”) in the UK, while SVN-002 is being advanced towards a planned Phase 2b trial in the United States targeting moderate-to-severe AUD. Solvonis is also advancing proprietary discovery and preclinical programmes across Post-Traumatic Stress Disorder (“PTSD”), stimulant use disorder and depressive disorders. These include SVN-114, a lead candidate from the Company’s PTSD discovery programme, and SVN-015, a novel serotonin-dopamine reuptake inhibitor being evaluated for stimulant use disorder, with additional depression-related optionality. In parallel, Solvonis is continuing to build its proprietary CNS discovery platform, supported by a dedicated compound library, to identify and develop new small-molecule modulators of key neurotransmitter systems relevant to addiction and psychiatry.

Phase 2Phase 3Executive Change

18 Jun 2026

·www.globenewswire.com

Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

SARASOTA, FLA., June 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC informing the Company that, as of June 17, 2026, it has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). Silo’s common stock continues to trade on the Nasdaq Capital Market, and the matter is now closed. “We appreciate the loyalty and continuing support from our investors for our business strategies aimed at creating long-term value for stockholders. Looking ahead, we remain confident about our progress toward a first-in-human clinical trial of our lead drug SPC-15 targeting PTSD and successfully advancing our AI agents platform QwikAgents,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. About Silo Pharma, Inc.Silo Pharma is a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer’s disease. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com Forward Looking StatementsThis news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about the intended use of proceeds from the offering, changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law. Contact(800) 705-0120investors@silopharma.com

18 Jun 2026

·www.biospace.com

HMNC Brain Health announces $50 million first closing of Series B financing and a strategic partnership with MEDICE

Financing will accelerate the development of HMNC’s neurosciences portfolio, including Phase 3-readiness activities for Ketabon (KET01) and Nelivabon (BH-200) Agreement grants MEDICE exclusive European commercialization rights for KET01, with tiered double-digit royalties and significant milestone payments MUNICH, Germany, June 15, 2026 – HMNC Brain Health ("HMNC" or the "Company"), a clinical-stage neuroscience company, today announced the successful $50 million first closing of its Series B financing to support the advancement of the Company’s Ketabon (KET01) and Nelivabon (BH-200) clinical programs. MEDICE – The Health Family (“MEDICE”) led the financing round as the main investor. MEDICE is one of the leading healthcare companies with a focus on mental health and is a market leader in the ADHD segment in several European countries. In addition, existing investor The Maschmeyer Group also participated in this round. Proceeds will support the late-stage clinical development of HMNC’s neuroscience portfolio, including Phase 3-readiness activities for Ketabon (KET01) and Nelivabon (BH-200). Ketabon (KET01) is an oral prolonged-release ketamine formulation for treatment-resistant depression (TRD), developed as a differentiated and scalable treatment option for outpatient and at-home use. Phase 2 studies have demonstrated rapid antidepressant effects and reduced dissociative side effects compared with existing ketamine-based therapies. Nelivabon (BH-200) is a first-in-class oral vasopressin V1b receptor antagonist being developed as a biomarker-guided precision therapy for biologically defined depressive disorders. The program has generated encouraging Phase 2b results in the OLIVE study and is supported by a proprietary genetic patient stratification approach. HMNC is also evaluating the potential expansion of the program into additional neuroscience indications. In parallel, MEDICE has entered into a strategic licensing agreement for the European commercialization of KET01. Under the terms of the agreement, HMNC and its affiliates are eligible to receive tiered double-digit royalties on net sales and significant success-based commercial milestone payments. The partnership combines HMNC’s differentiated neuroscience pipeline and precision capabilities with MEDICE’s established European commercial infrastructure in the field of mental health. Dr. Maximilian Doebler, Managing Director & Chief Business Officer, HMNC , said: “Securing this financing alongside a strategic partner like MEDICE validates our scientific approach and our broader vision of building a next-generation neuroscience company. MEDICE brings the expertise and commercial infrastructure to help bring KET01 to patients at scale, and we are excited to partner with such an experienced and highly regarded team.” Dr. Dr. Jessica Burgstaller, VP Strategy & Corporate Development, HMNC , said: “This partnership is an important step toward bringing our scientific insights closer to patients. Seeing years of research translate into meaningful new treatment options for patients further strengthens our conviction that precision neuroscience can reshape mental health treatment. At the same time, we are committed to improving access to safe and rapid-acting ketamine-based therapies.” “Mental health is at the heart of what MEDICE does, and Ketabon represents a compelling opportunity to expand our presence in depression treatment with a differentiated approach. We are also excited by the potential of HMNC’s biomarker-guided precision portfolio, including Nelivabon, which reflects where we believe the field is heading. By combining MEDICE’s commercial infrastructure and neuropsychiatry expertise with HMNC’s innovation capabilities, we are well positioned to help bring these programs to patients across Europe,” said Dr. med. Katja Pütter-Ammer, Managing Partner of MEDICE. KET01 and BH-200 are investigational therapies and are not approved by regulatory authorities. -END- Contact HMNC Brain Health Dr. Maximilian Doebler, Managing Director & Chief Business Officer E-mail: maximilian.doebler@hmnc-brainhealth.com Dr. Dr. Jessica Burgstaller, VP Strategy & Corporate Development E-mail: jessica.burgstaller@hmnc-brainhealth.com MEDICE – The Health Family Harald Goeßl, Head of Corporate Communications E-mail: H.Goessl@medice.de ICR Healthcare Tracy Cheung / Ashley Tapp / Kris Lam E-mail: HMNCBrainHealth@icrhealthcare.com About HMNC Brain Health (HMNC Holding GmbH) HMNC Brain Health (HMNC) is a clinical-stage neuroscience company pioneering new therapies for mental health disorders. Its pipeline includes Nelivabon (BH-200), a vasopressin V1b receptor antagonist being developed as a biomarker-guided precision therapy for biologically defined depressive disorders. Used with a genetic test to identify patients most likely to benefit, Nelivabon offers a precision neuroscience approach to treatment. HMNC is also developing Ketabon (KET01), an oral prolonged-release ketamine formulation for treatment-resistant depression, designed as a differentiated and scalable option for outpatient and at-home use. By advancing targeted and accessible treatment options, HMNC aims to address significant unmet needs of millions of patients who are not helped sufficiently by existing mental health therapies. The Company is headquartered in Munich, Germany. Find out more at and connect with us on LinkedIn . About the Ketabon Program Ketabon is a joint venture between HMNC Brain Health and Develco Pharma focused on developing KET01, an oral prolonged-release ketamine formulation for treatment-resistant depression (TRD). Designed for safe and convenient at-home treatment, KET01 has demonstrated rapid antidepressant effects with minimal dissociative side effects in Phase 2 studies, potentially offering an important differentiated alternative to existing ketamine-based therapies. About MEDICE – The Health Family MEDICE – The Health Family is a third-generation, family-run pharmaceutical company, operating for over 75 years, that focuses on providing integrated, multimodal healthcare solutions. The company develops high-quality prescription (RX) and self-medication (PCC) products, alongside digital health and nutritional concepts. View the full company pro Welcome to the MEDICE Health Family .

100 Deals associated with Ketamine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00711	Ketamine Hydrochloride	N01AX03	DBSALT000396

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pain	United States	Pharmather Holdings Ltd.	08 Aug 2025
Anesthesia	United States	Ph Healthcare Services	19 Feb 1970

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Suicidal Ideation	NDA/BLA	United States	Pharmather Holdings Ltd.	11 Mar 2025
Bipolar and Related Disorders	Phase 3	United States	NeuroRx, Inc.	30 Jan 2022
Bipolar Disorder	Phase 3	United States	NeuroRx, Inc.	25 Jun 2019
Alcohol Use Disorder	Phase 3	United Kingdom	Solvonis Therapeutics Plc	-
Stress Disorders, Post-Traumatic	Phase 2	United States	Seelos Therapeutics, Inc.	27 Nov 2023
Rett Syndrome	Phase 2	United States	Pharmather Holdings Ltd.	02 Feb 2023
Dyskinesia, Drug-Induced	Phase 2	United States	Pharmather, Inc.	05 Oct 2021
Parkinson Disease	Phase 2	United States	Pharmather, Inc.	05 Oct 2021
Cluster Headache	Phase 2	Denmark	Cch Pharma Pty Ltd.	20 Nov 2019
Depressive Disorder, Major	Phase 2	Australia	Douglas Pharmaceuticals Ltd.	30 May 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04955470 (Pubmed \| CJEM)	Phase 2	Suicidal Ideation	15	Intravenous ketamine (0.5 mg/kg)	wqrfhsfylk(qnhqenndon) = No serious or unexpected adverse events occurred. wgjewedmiz (gcsbphxedv )	Positive	03 Jun 2026
				Midazolam (0.03 mg/kg)
NCT01969227 (CTgov)	Not Applicable	Airway Obstruction	15	Propofol+Ketamine	tjaijhzrsp(adhrvbimok) = ugdyjbgchm pwvzyyrkrm (upwobnrpsa, cnbztsnhwc - dsrfeeslcl) View more	-	19 May 2026
NCT03470675 (CTgov)	Phase 4	Depression, Postpartum \| Perineal pain	67	Epidural saline + IV saline (Epidural Saline + IV Saline)	zdttvkufth(jqdexilnyn) = roydwvvooi ntlqugpxse (qlzpwruccr, ppqktcnjsi - caivtlwcno) View more	-	24 Apr 2026
				Epidural morphine 3 mg + IV saline (Epidural Morphine 3 mg + IV Saline)	zdttvkufth(jqdexilnyn) = smdvllbpfs ntlqugpxse (qlzpwruccr, hgzuexpzfu - mcajqrbdue) View more
NCT06317636 (Pubmed \| Pain Manag)	Phase 2	Depressive Disorder \| Chronic Pain	42	Ketamine	rgmfngplro(wowbnsyqyg) = gytpghoqkf xmvyddydnl (bilenddkey ) View more	Positive	16 Apr 2026
NCT05518877 (CTgov)	Phase 4	Analgesia \| Acute Pain	55	Ketamine (Ketamine 15 Minutes)	rnfpllxtyc(zwtvmnuewa) = jyvcrdpcfx khoktmtllc (qxkjtgdjbq, 0.57) View more	-	13 Apr 2026
				ketamine (Ketamine 30 Minutes)	rnfpllxtyc(zwtvmnuewa) = bgchnwnnky khoktmtllc (qxkjtgdjbq, 0.25) View more
NCT06138691 (KET-RO, CTgov)	Phase 1	Depressive Disorder, Treatment-Resistant	16	RO+Ketamine (Ketamine and RO DBT)	tqepronfat(qheysqfbjv) = jwlwxkqhtk fsawgmogtg (rgrpslnitb, 8.69) View more	-	30 Mar 2026
				RO+Ketamine (Within Ketamine Session and Ketamine + RO DBT)	qletistxgp(wclsfbixdu) = xmzhzqyztl lkkvjtisbn (gohkublyiy, 14.97) View more
NCT05277896 (RSI, CTgov)	Phase 4	Respiratory Failure	2,367	Ketamine (Ketamine Group)	jdehiypfnp = wbeygjvhmx uisukqcgzn (enapufgmtl, xvowifewsm - aysaprluqh) View more	-	25 Mar 2026
				Etomidate (Etomidate Group)	jdehiypfnp = mohfpghfey uisukqcgzn (enapufgmtl, bbdjfinjlh - ysuswvpitn) View more
NCT07059429 (KETARTHRO, CTgov)	Not Applicable	Opioid abuse \| Analgesia \| Pain, Postoperative	100	ketamine (Ketamine Plus Standard Analgesia)	dikpniqfsu(casnicplnm) = cakssicpao qyiqrqbecp (klfwyrgayr, wxbyyopfcl - tlsghepuvz) View more	-	02 Mar 2026
				Standard Analgesia (Standard Analgesia Alone)	dikpniqfsu(casnicplnm) = qdhfpyzcau qyiqrqbecp (klfwyrgayr, wnmvgceylr - rzrsewewjd) View more
NCT07337135 (CTgov)	Not Applicable	Complications of bariatric procedures \| Anesthesia \| Pain, Postoperative ... View more	60	Remifentanil (Opioid-Based Anesthesia (OBA))	cqcdgocezt(kgameknpwr) = qhtldfihmj hughevccmf (huojzsrpxd, nkiicwryfc - ohapbmgsvj) View more	-	25 Feb 2026
				Dexmedetomidine+Lidocaine+Ketamine (Opioid-Free Anesthesia (OFA))	cqcdgocezt(kgameknpwr) = mzxfbqijph hughevccmf (huojzsrpxd, cgziyibhlp - wcudawroqp) View more
NCT05320107 \| NCT05320120 (Pubmed \| Ther Adv Psychopharmacol)	Phase 1	-	67	S-ketamine	eekhjawpfj(pvcsazuvar) = late ketamine administration resulted in reduced calcarine gyrus activation in men compared to women, independent of sexual arousal (β ≤ −0.23, CI 95 ≤ (−0.52, 0.05)). This finding was confirmed for resting activity under subacute ketamine (β = −0.18, CI 95 = (−0.32, −0.04)) zrzqhyflns (dnispfarkl ) View more	Negative	01 Feb 2026
				Racemic ketamine